Home » Emerging Markets Encouraged to Focus on Most Likely Counterfeits
Emerging Markets Encouraged to Focus on Most Likely Counterfeits
June 7, 2012
Drugmakers breaking into emerging markets could see supply chain benefits and quicker product launches if these markets automatically registered U.S. Food and Drug Administration (FDA)-approved products before testing for quality issues, according to a new study.
To View This Article:
Subscribe To International Pharmaceutical Regulatory Monitor